The approval for the drug, which comes after an initial rejection from the FDA in January last year, lifted Pfizer’s shares marginally and Opko Health over 27% in premarket trading., The approval for the drug, which comes after an initial rejection from the FDA in January last year, lifted Pfizer’s shares marginally and Opko Health over 27% in premarket trading., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way